Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q14671
UPID:
PUM1_HUMAN
Alternative names:
-
Alternative UPACC:
Q14671; A8K6W4; B4DG92; D3DPN3; E9PCJ0; Q53HH5; Q5VXY7; Q9HAN1
Background:
Pumilio homolog 1 (PUM1) is a sequence-specific RNA-binding protein, crucial for post-transcriptional regulation. It binds to the Pumilio Response Element on mRNA targets, leading to repression via mechanisms like deadenylation and miRNA accessibility. PUM1 plays a pivotal role in cell cycle entry, genomic stability, neuronal functions, and embryonic stem cell renewal.
Therapeutic significance:
Spinocerebellar ataxia 47, a disorder marked by incoordination and developmental disability, is linked to PUM1 gene variants. Understanding PUM1's role could unveil new therapeutic strategies for this and potentially other neurological conditions.